Skip NavigationSkip to Content
Return Return to Search Results

Botryllamides: Natural Product Inhibitors of ABCG2

  1. Author:
    Henrich, C. J.
    Robey, R. W.
    Takada, K.
    Bokesch, H. R.
    Bates, S. E.
    Shukla, S.
    Ambudkar, S. V.
    McMahon, J. B.
    Gustafson, K. R.

  2. Author Address

    Henrich, Curtis J.; Bokesch, Heidi R.] SAIC Frederick Inc, Basic Res Program, Frederick, MD USA. [Henrich, Curtis J.; Takada, Kentaro, Bokesch, Heidi R.; McMahon, James B.; Gustafson, Kirk R.] NCI Frederick, Mol Targets Dev Program, Frederick, MD USA. [Robey, Robert W.; Bates, Susan E.] NCI, Med Oncol Branch, Bethesda, MD 20892 USA. [Shukla, Suneet, Ambudkar, Suresh V.] NCI, Cell Biol Lab, Bethesda, MD 20892 USA.
    1. Year: 2009
  2. Journal: Acs Chemical Biology
    1. 4
    2. 8
    3. Pages: 637-647
  4. Type of Article: Article
  1. Abstract:

    ABCG2 is a membrane-localized, human transporter protein that has been demonstrated to reduce the intracellular accumulation of substrates through ATP-dependent efflux. Highly expressed in placental syncytiotrophoblasts, brain microvasculature, and the gastrointestinal tract, ABCG2 has been shown to mediate normal tissue protection as well as limit oral bioavailability of substrate compounds. Development of ABCG2 Inhibitors for clinical use may allow increased penetration of therapeutic agents into sanctuary sites and increased gastrointestinal absorption. Previously identified inhibitors have lacked potency or specificity or were toxic at concentrations needed to inhibit ABCG2, none are in clinical development A previously developed high-throughput assay measuring inhibition of ABCG2-mediated pheophorbide a transport was applied to natural product extract libraries. Among the active samples were extracts from the marine ascidian Botryllus tyreus. Bioassay-guided fractionation resulted in purification of a series of botryllamides. Ten botryllamides were obtained, two of which (designated I and J) were novel. Activity against ABCG2 was confirmed by assessing the ability of the compounds to inhibit ABC62-mediated BODIPY-prazosin transport in ABCG2-transfected HEK293 cells, compete with [I-125]-iodoarylazidoprazosin (IAAP) labeling of ABCG2, stimulate ABCG2-associated ATPase activity and reverse ABCG2-mediated resistance.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1021/cb900134c
  3. PMID: 19555120

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel